The Canaccord Genuity Analysts Give Entellus Medical Inc (ENTL) a $18.00 Price Target

The Canaccord Genuity Analysts Give Entellus Medical Inc (ENTL) a $18.00 Price Target

A number of other equities research analysts have also recently issued reports on the stock. William Blair reaffirmed an outperform rating on shares of Entellus Medical in a research note on Wednesday, May 10th. Zacks Investment Research cut shares of Entellus Medical from a hold rating to a sell rating in a research note on Tuesday, May 9th. Bank of America Corp cut shares of Entellus Medical from a buy rating to an underperform rating and set a $16.00 price objective for the company. in a research note on Wednesday, February 22nd. Finally, BTIG Research cut shares of Entellus Medical from a buy rating to a neutral rating in a research report on Wednesday, February 22nd. Three analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $21.83.

Canaccord Genuity set a $18.00 price objective on Entellus Medical Inc (NASDAQ:ENTL) in a research note issued to investors on Monday, May 22nd. The brokerage currently has a hold rating on the medical technology company’s stock.

Entellus Medical (NASDAQ:ENTL) opened at 13.66 on Monday. Entellus Medical has a one year low of $11.47 and a one year high of $22.63. The stock has a 50 day moving average price of $13.67 and a 200 day moving average price of $15.92. The firm’s market capitalization is $299.37 million. Entellus Medical (NASDAQ:ENTL) last issued its quarterly earnings results on Wednesday, May 3rd. The medical technology company reported ($0.40) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.44) by $0.04. The firm had revenue of $19.11 million for the quarter, compared to analyst estimates of $19.61 million. Entellus Medical had a negative net margin of 36.91% and a negative return on equity of 53.20%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.37) EPS. On average, equities analysts predict that Entellus Medical will post ($1.36) EPS for the current fiscal year.

Entellus Medical (NASDAQ:ENTL) opened at 13.66 on Monday. Entellus Medical has a one year low of $11.47 and a one year high of $22.63. The stock has a 50 day moving average price of $13.67 and a 200 day moving average price of $15.92. The firm’s market capitalization is $299.37 million. In other news, insider Robert S. White acquired 10,000 shares of Entellus Medical stock in a transaction on Monday, May 8th. The stock was acquired at an average cost of $12.24 per share, for a total transaction of $122,400.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Brent Moen acquired 6,100 shares of Entellus Medical stock in a transaction on Monday, May 8th. The shares were purchased at an average price of $12.21 per share, with a total value of $74,481.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 17,700 shares of company stock valued at $216,625. 9.10% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. Arrowpoint Asset Management LLC increased its position in Entellus Medical by 39.9% in the fourth quarter. Arrowpoint Asset Management LLC now owns 312,634 shares of the medical technology company’s stock worth $5,931,000 after buying an additional 89,158 shares during the last quarter. Renaissance Technologies LLC increased its position in Entellus Medical by 23.1% in the fourth quarter. Renaissance Technologies LLC now owns 78,800 shares of the medical technology company’s stock worth $1,495,000 after buying an additional 14,800 shares during the last quarter. Eqis Capital Management Inc. increased its position in Entellus Medical by 22.8% in the first quarter. Eqis Capital Management Inc. now owns 33,475 shares of the medical technology company’s stock worth $462,000 after buying an additional 6,223 shares during the last quarter. William Blair Investment Management LLC increased its position in Entellus Medical by 1,017.0% in the first quarter. William Blair Investment Management LLC now owns 390,334 shares of the medical technology company’s stock worth $5,387,000 after buying an additional 355,388 shares during the last quarter. Finally, State Street Corp increased its position in Entellus Medical by 8.5% in the fourth quarter. State Street Corp now owns 105,783 shares of the medical technology company’s stock worth $2,007,000 after buying an additional 8,251 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors. About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:ENTL”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Related posts

Leave a Comment